Spots Global Cancer Trial Database for iron overload
Every month we try and update this database with for iron overload cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Massive Iron Deposit Assessment | NCT01572922 | Iron Overload Excessive Body ... | R2*-UTE R2*-GRE Liver biopsy | - | St. Jude Children's Research Hospital | |
| Transfusional Iron Overload Among Leukemia Survivors | NCT01965171 | Acute Lymphocyt... Acute Myeloid L... | 5 Years - | St. Jude Children's Research Hospital | ||
| Iron Overload in Pediatric Oncology Patients | NCT01034072 | Iron Overload | 78 Months - 25 Years | Northwell Health | ||
| Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome | NCT01892644 | Hemochromatosis Myelodysplastic... | Deferasirox Venesection Deferasirox | 18 Years - 80 Years | Haukeland University Hospital | |
| Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation | NCT00658411 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... | deferoxamine | 18 Years - | Dana-Farber Cancer Institute | |
| Iron Overload in Pediatric Oncology Patients | NCT01034072 | Iron Overload | 78 Months - 25 Years | Northwell Health | ||
| Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients | NCT00117507 | Myelodysplastic... Iron Overload | Deferasirox | 18 Years - | Novartis | |
| Massive Iron Deposit Assessment | NCT01572922 | Iron Overload Excessive Body ... | R2*-UTE R2*-GRE Liver biopsy | - | St. Jude Children's Research Hospital | |
| Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation | NCT00658411 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... | deferoxamine | 18 Years - | Dana-Farber Cancer Institute | |
| This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. | NCT01250951 | Myelodysplastic... Thalassemia | Deferasirox | 2 Years - | Novartis | |
| Iron Overload in Pediatric Oncology Patients | NCT01034072 | Iron Overload | 78 Months - 25 Years | Northwell Health | ||
| Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology Group | NCT03141398 | Iron Overload Hemoglobinopath... Lymphoma Acute Lymphobla... | Continuous Gluc... Oral Glucose To... T2* MRI of the ... | 14 Years - | Hamad Medical Corporation | |
| Phlebotomy and Risk of Hepatocellular Carcinoma in Patients With Compensated Alcoholic Cirrhosis | NCT01342705 | Alcoholic Cirrh... Iron Overload | phlebotomy | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome | NCT01892644 | Hemochromatosis Myelodysplastic... | Deferasirox Venesection Deferasirox | 18 Years - 80 Years | Haukeland University Hospital | |
| Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome | NCT01892644 | Hemochromatosis Myelodysplastic... | Deferasirox Venesection Deferasirox | 18 Years - 80 Years | Haukeland University Hospital | |
| Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload | NCT02833493 | Aplastic Anemia Dysmyelopoietic... Iron Overload | 18 Years - 80 Years | Peking Union Medical College Hospital | ||
| Observational Study of Iron Overload in Stem Cell Transplantation | NCT00954720 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... | No Intervention | 18 Years - 65 Years | Dana-Farber Cancer Institute | |
| Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant | NCT00602446 | Breast Cancer Iron Overload Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Neuroblastoma Ovarian Cancer | deferasirox | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
